People who got the injection, retatrutide, lost 28 percent of their body weight on average after 80 weeks, Eli Lilly said.
Category: GLP-1 RAs (Drug)
-
Medicare Coverage for GLP-1 Weight Loss Drugs: Cost, Eligibility and What to Know
What you should know about the federal government’s pilot program offering GLP-1s solely for weight loss.
-
How A.I. Helped One Man (and His Brother) Build a $1.8 Billion Company
Who needs more than two employees when artificial intelligence can do so many corporate tasks? It’s super efficient — and a little bit lonely.
-
Ozempic Is About to Go Generic in India, China and Canada
In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions.
-
Weight-Loss Drugs Could Save U.S. Airlines $580 Million Per Year
A study by the financial firm Jefferies highlights a surprising perk for carriers: lower fuel costs as slimmer passengers lighten their aircrafts’ loads.
-
‘Chinese Peptides’ Are the Latest Biohacking Trend in the Tech World
The gray-market drugs flooding Silicon Valley reveal a community that believes it can move faster than the F.D.A.
-
New Eli Lilly Drug Retatrutide Brought Major Weight Loss in Trial
The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.
-
U.S. Announces Negotiated Prices for 15 Drugs Under Medicare
The Trump administration said that had the new prices been in effect last year, Medicare would have saved $12 billion, which would have reduced its spending on those drugs by 44 percent.
-
Ozempic Drug Fails to Quell Alzheimer’s in Novo Nordisk Trials
The studies were a significant setback for the optimistic view that semaglutide and other GLP-1 drugs could help prevent a number of brain diseases.
-
Eli Lilly, Drug Maker of Zepbound and Mounjaro, Reaches $1 Trillion in Value
The 150-year-old drugmaker is the first company in health care to hit the milestone.
-
Kennedy Walks a Tightrope on Trump Deal for Obesity Drugs
The weight loss medicines are proving to be a test case for Robert F. Kennedy Jr., the health secretary, in straddling divisions between his supporters and the president.
-
Pfizer to Acquire Obesity Drug Start-Up Metsera in $10 Billion Deal
The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker of Ozempic and Wegovy.